Conference Coverage

Three days of beta-lactam beat clinically stable CAP



– Three days of beta-lactam therapy was just as effective as 8 days for clinically stable patients presenting with community-acquired pneumonia.

In a randomized, placebo-controlled trial, 15-day cure rates were 69.9% in patients who took 3 days of antibiotics and 61.2% in those who took 8 days – a nonsignificant difference, Aurélien Dinh, MD, said at the European Society of Clinical Microbiology and Infectious Diseases annual congress.

Dr. Aurélien DinhUniversity of Paris Hospital Michele G Sullivan/MDedge News

Dr. Aurélien Dinh

The French study was one of a series at the meeting demonstrating that, for some groups of patients, short-term antibiotic therapy is a viable – and probably healthy – alternative to the traditional longer courses, said Dr. Dinh of the University of Paris Hospital.

“Reducing treatment time now appears to be manageable and effective in a number of infectious diseases,” Dr. Dinh explained. “Although there are some limits, surely, this change in practice might lead to reduced rates of multidrug-resistant bacteria, fewer adverse events, and surely lower costs.”

The French PTC Trial (Short Duration Treatment of Non-Severe Community-Acquired Pneumonia) randomized 310 patients (mean age, 73.5 years) to either short- or long-course treatment with a beta-lactam antibiotic. Patients were eligible for the study if they were admitted to the hospital for community-acquired pneumonia based on respiratory signs, fever of 38° C or higher, and evidence of new infiltrate on chest radiograph.

All patients were treated with 3 days of amoxicillin/clavulanic acid (Augmentin) or third-generation cephalosporin. Those who had responded clinically by day 3 entered the 5-day randomization period, receiving placebo or 5 more days of active therapy with the same agent.

Clinical requirements for randomization included being afebrile with stable heart and respiratory rate, a systolic blood pressure of at least 90 mm Hg, and oxygen saturation of at least 90%.


Recommended Reading

Predicting MDR Gram-negative infection mortality risk
The Hospitalist
Is it time for health policy M&Ms?
The Hospitalist
Drug combo indicated for bacterial pneumonia
The Hospitalist
Paring the risk of antibiotic resistance
The Hospitalist
Reported penicillin allergies hike inpatient costs
The Hospitalist
FDA warns against clarithromycin use in patients with heart disease
The Hospitalist
Making structural improvements in health care
The Hospitalist
Unusual antibiotic resistance found in more than 200 bacteria
The Hospitalist
Don’t shorten therapy for older, sicker cellulitis patients
The Hospitalist
ESBL-resistant bacteria spread in hospital despite strict contact precautions
The Hospitalist
   Comments ()